AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE

Amgen's Repatha cuts death risk by 20% in heart study (AMGN:NASDAQ)

Amgen’s Phase 3 VESALIUS-CV data show Repatha cut death risk 20% in high-risk adults on statins—see ESC 2026 findings and key takeaways.

AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE

Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention Patients in a Phase 3 Trial

Amgen Drug Cuts The Risk Of Dying By 20%

Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients.

A cholesterol drug lowered death risk 20% in people yet to have a first heart attack or stroke

In more than 12,000 patients, the reduction in deaths began after about 1.5 years; median follow-up was 4.6 years, and heart attack risk fell 36%.

One Of Amgen's Biggest Moneymakers Cuts The Risk Of Dying By 20%

Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients. The post One Of Amgen's Biggest Moneymakers Cuts The Risk Of Dying By 20% appeared first on Investor's Business Daily.